Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Sesen learns a lesson in investor relations
Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
